Gantenerumab in- depth outcomes
Salloway, Stephen P.; Bateman, Randall J.; Aschenbrenner, Andrew J.; Benzinger, Tammie L.S.; Clifford, David; Coalier, Kelley; Cruchaga, Carlos; Fagan, Anne M.; Farlow, Martin R.; Goate, Alison M.; Gordon, Brian A.; Hassenstab, Jason; Jack, Clifford R.; Koeppe, Robert A.; McDade, Eric; Mills, Susan; Morris, John C.; Santacruz, Anna; Snyder, Peter J.; Wang, Guoqiao; Xiong, Chengjie; Snider, B. Joy; Mummery, Catherine J.; Surti, Ghulam M.; Hannequin, Didier; Wallon, David; Berman, Sarah; Lah, James J.; Jiménez‐velazquez, Ivonne Z.; Roberson, Erik D.; van Dyck, Christopher H.; Honig, Lawrence S.; Sanchez‐valle, Raquel; Brooks, William S.; Gauthier, Serge; Masters, Colin L.; Galasko, Doug R.; Brosch, Jared R.; Hsiung, Ging‐yuek Robin; Jayadev, Suman; Formaglio, Maïté; Masellis, Mario; Clarnette, Roger; Pariente, Jeremie; Dubois, Bruno; Pasquier, Florence; Baudler, Monika; Delmar, Paul; Doody, Rachelle; Fontoura, Paulo; Kerchner, Geoffrey A.
2020-12
Citation
Salloway, Stephen P.; Bateman, Randall J.; Aschenbrenner, Andrew J.; Benzinger, Tammie L.S.; Clifford, David; Coalier, Kelley; Cruchaga, Carlos; Fagan, Anne M.; Farlow, Martin R.; Goate, Alison M.; Gordon, Brian A.; Hassenstab, Jason; Jack, Clifford R.; Koeppe, Robert A.; McDade, Eric; Mills, Susan; Morris, John C.; Santacruz, Anna; Snyder, Peter J.; Wang, Guoqiao; Xiong, Chengjie; Snider, B. Joy; Mummery, Catherine J.; Surti, Ghulam M.; Hannequin, Didier; Wallon, David; Berman, Sarah; Lah, James J.; Jiménez‐velazquez, Ivonne Z. ; Roberson, Erik D.; van Dyck, Christopher H.; Honig, Lawrence S.; Sanchez‐valle, Raquel ; Brooks, William S.; Gauthier, Serge; Masters, Colin L.; Galasko, Doug R.; Brosch, Jared R.; Hsiung, Ging‐yuek Robin ; Jayadev, Suman; Formaglio, Maïté ; Masellis, Mario; Clarnette, Roger; Pariente, Jeremie; Dubois, Bruno; Pasquier, Florence; Baudler, Monika; Delmar, Paul; Doody, Rachelle; Fontoura, Paulo; Kerchner, Geoffrey A. (2020). "Gantenerumab in- depth outcomes." Alzheimer’s & Dementia 16: n/a-n/a.
Abstract
BackgroundGantenerumab is a humanized anti- amyloid- beta monoclonal antibody in clinical development for the treatment of several stages of Alzheimer disease (AD). Gantenerumab was evaluated in a phase 2/3 clinical trial program designed to evaluate its efficacy in autosomal dominant AD based on a combination of clinical and biomarker evidence.MethodThe study enrolled both mutation carriers (n=69 with 3:1 randomization of treatment (n=52) vs placebo (n=17)) and non- carriers (n=28, all on placebo) from 15 years before to 10 years after the expected age of onset inclusive. Patients were both asymptomatic (CDR 0 and MMSE >25) and symptomatic (CDR 0.5- 1 and MMSE >16). There were 41 asymptomatic and 28 symptomatic mutation carriers. The initial dose of gantenerumab was 225 mg monthly administered subcutaneously. The dose was titrated to 1200 mg/month following a protocol amendment based on the increased amyloid lowering seen at higher doses in the gantenerumab program in symptomatic AD. The treatment duration was a minimum of 4 years (range 48- 80 months). The primary outcome was change from baseline in the DIAN- TU multivariate cognitive endpoint. Secondary clinical outcomes included the DIAN- TU cognitive composite, Cogstate multivariate cognitive endpoint, CDR SB, and time to CDR progression of >0.5 points. Change from baseline in amyloid PET was the primary biomarker outcome. Other biomarker outcomes included MRI, tau PET, CSF amyloid, tau and phosphotau, and CSF and plasma neurofilament light (NfL). Safety outcomes including ARIA were compared between drug and placebo groups.ResultWe will report change from baseline on the DIAN- TU multivariate cognitive endpoint, DIAN- TU cognitive composite, CDR- SB and other secondary efficacy endpoints. We expect significant lowering on amyloid PET with PIB and florbetapir based on the results from recent anti- amyloid antibodies, including Gantenerumab, in sporadic AD. We will also present the results of change in other key imaging and fluid biomarkers. The frequency, duration, and severity of ARIA will be reported and compared with studies in sporadic AD.ConclusionThis clinical trial was designed to inform future for ADAD and will provide new insights on the role of amyloid reduction in both pre- symptomatic and clinical AD.Publisher
Wiley Periodicals, Inc.
ISSN
1552-5260 1552-5279
Other DOIs
Types
Article
Metadata
Show full item recordCollections
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.